Xaliproden
Xaliproden
Xaliproden (pronounced: zah-lih-PRO-den) is a neuroprotective agent that was under development for the treatment of Amyotrophic lateral sclerosis (ALS) and chemotherapy-induced peripheral neuropathy (CIPN).
Etymology
The term "Xaliproden" is a coined name, with no specific etymology. It is a common practice in pharmaceutical naming to create unique, non-descriptive names for new drugs.
Usage
Xaliproden was investigated for its potential to slow the progression of ALS, a neurodegenerative disease that affects nerve cells in the brain and spinal cord. It was also studied for its potential to prevent or reduce CIPN, a common side effect of certain chemotherapy drugs.
Mechanism of Action
Xaliproden is believed to work by protecting nerve cells from damage. It is a serotonin 1A receptor agonist, which means it binds to and activates these receptors in the brain. This activation is thought to have neuroprotective effects.
Clinical Trials
Several clinical trials were conducted to evaluate the safety and efficacy of Xaliproden in patients with ALS and CIPN. However, the drug did not show sufficient benefit in these trials and development was discontinued.
Related Terms
- Neuroprotection
- Amyotrophic lateral sclerosis
- Chemotherapy-induced peripheral neuropathy
- Serotonin
- Clinical trials
External links
- Medical encyclopedia article on Xaliproden
- Wikipedia's article - Xaliproden
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski